Investors in digital health are a different breed. They invest less than life science investors, and they expect (and receive) more rapid returns. What's more, the corporate, strategic investment funds are not simply the venture arms of big pharma and medtech; health insurers and the tech firms are in there, too. And, guess what – they have entirely different agendas.
In Vivo has looked at 267 venture capital investments in digital health in 2017 with a composite value of $6.13 billion. The analysis looks at patterns of investments, what kind of companies are getting funded, and the nature of the investing participants.
A few observations stand out immediately:
During Q2, biopharmas brought in an aggregate $17.5bn in financing and device company fundraising totaled $2.7bn; while in vitro diagnostic firms and research tools players raised $1.7bn
IMMA’s transvaginal at-home ovarian stimulation monitoring system using ultrasound and AI image analysis increases the chances of early IVF success. It won the Biomed Israel 2025 IVD start-up showcase award. Further potential applications could follow, cofounder/CEO Beatrice Chemla told In Vivo.
Replimune's RP1 oncolytic immunotherapy became the third regenerative medicine to receive an FDA complete response letter this month as the agency appears to re-visit previous agreements about accelerated approval.
